Literature DB >> 18772674

Epithelial tumors of the lacrimal gland: an update.

Francesco P Bernardini1, Martìn H Devoto, J Oscar Croxatto.   

Abstract

PURPOSE OF REVIEW: The goal of this article is to offer an update on the treatment and prognosis of the most common epithelial tumors of the lacrimal gland, report on new pathological entities and offer a review of the classification of lacrimal gland tumors. RECENT
FINDINGS: Improvements have been made in the understanding of lacrimal gland lesions with the knowledge that lacrimal gland tumors compare to the more common counterparts of the major salivary glands. Therefore, the WHO's classification of salivary gland tumors has been adapted to the lacrimal gland pathology. Until recently, primary adenocarcinomas of the lacrimal gland were not further subclassified, but they can now be divided into low-grade and high-grade malignancies. The adjunctive use of intra-arterial cytoreductive chemotherapy for the management of adenoid cystic carcinoma is one of the most important advancements on the management of these aggressive tumors. Another important step forward has been taken on carcinoma ex pleomorphic adenoma of the lacrimal gland, which is subclassified into noninvasive carcinoma, with an excellent prognosis after complete excision and invasive carcinoma for which the prognosis is still guarded despite adjunctive radiotherapy.
SUMMARY: This article offers an update on diagnosis, classification and treatment of common and rare epithelial lacrimal gland tumors.

Entities:  

Mesh:

Year:  2008        PMID: 18772674     DOI: 10.1097/ICU.0b013e32830b13e1

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  15 in total

1.  Adenoid cystic carcinoma of the lacrimal gland is frequently characterized by MYB rearrangement.

Authors:  T Y Chen; M G Keeney; A V Chintakuntlawar; D L Knutson; S Kloft-Nelson; P T Greipp; J A Garrity; D R Salomao; J J Garcia
Journal:  Eye (Lond)       Date:  2017-01-13       Impact factor: 3.775

2.  Evolution of Care of Orbital Tumors with Radiation Therapy.

Authors:  Myrsini Ioakeim-Ioannidou; Shannon M MacDonald
Journal:  J Neurol Surg B Skull Base       Date:  2020-08-24

3.  Pleomorphic Adenoma with Sarcomatous Change in a Lacrimal Gland.

Authors:  Kyoung-Su Sung; Dae-Cheol Kim; Hee-Bae Ahn; Young-Jin Song
Journal:  J Korean Neurosurg Soc       Date:  2015-06-30

4.  Primary adenocarcinoma of the lacrimal gland.

Authors:  Sang-Oon Baek; Yoon-Jae Lee; Suk-Ho Moon; Young-Jin Kim; Young-Joon Jun
Journal:  Arch Plast Surg       Date:  2012-09-12

5.  Mucoepidermoid carcinoma ex pleomorphic adenoma of the lacrimal gland: a rare presentation.

Authors:  Lily Daniel; Shalinee Rao; Radhakrishnan Muthusamy; Deepika Yerramsetti
Journal:  Indian J Ophthalmol       Date:  2014-06       Impact factor: 1.848

6.  Adjuvant Radiotherapy with Three-Dimensional Conformal Radiotherapy of Lacrimal Gland Adenoid Cystic Carcinoma.

Authors:  Vikas Roshan; Sushmita Pathy; Supriya Mallick; Subhash Chander; Seema Sen; Bhavna Chawla
Journal:  J Clin Diagn Res       Date:  2015-10-01

Review 7.  Rare Diseases of the Orbit.

Authors:  Ulrich Kisser; Jens Heichel; Alexander Glien
Journal:  Laryngorhinootologie       Date:  2021-04-30       Impact factor: 1.057

8.  Epithelial lacrimal gland tumors: A comprehensive clinicopathologic review of 26 lesions with radiologic correlation.

Authors:  Hind M Alkatan; Dora Hamad Al-Harkan; Mohammed Al-Mutlaq; Azza Maktabi; Sahar M Elkhamary
Journal:  Saudi J Ophthalmol       Date:  2014-01-06

9.  [Exophthalmos of the left eye in favor of orbital adenoid cystic carcinoma: report of a case].

Authors:  Adil Bouzidi; Said Iferkhass; Zine El Abidine Hansali; Mohammed Elmallaoui; Abdelkader Laktaoui
Journal:  Pan Afr Med J       Date:  2015-10-21

10.  Whole Exome Sequencing of Lacrimal Gland Adenoid Cystic Carcinoma.

Authors:  David W Sant; Wensi Tao; Matthew G Field; Daniel Pelaez; Ke Jin; Anthony Capobianco; Sander R Dubovy; David T Tse; Gaofeng Wang
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-05-01       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.